These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 10348091)

  • 21. Potential cardiac toxicity of H1-antihistamines.
    Yap YG; Camm AJ
    Clin Allergy Immunol; 2002; 17():389-419. PubMed ID: 12113224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes.
    Hey JA; del Prado M; Kreutner W; Egan RW
    Arzneimittelforschung; 1996 Feb; 46(2):159-63. PubMed ID: 8720305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiac safety of second-generation H
    Cataldi M; Maurer M; Taglialatela M; Church MK
    Clin Exp Allergy; 2019 Dec; 49(12):1615-1623. PubMed ID: 31519068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of urticaria. An evidence-based evaluation of antihistamines.
    Lee EE; Maibach HI
    Am J Clin Dermatol; 2001; 2(1):27-32. PubMed ID: 11702618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ebastine. a review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders.
    Wiseman LR; Faulds D
    Drugs; 1996 Feb; 51(2):260-77. PubMed ID: 8808167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. H1-antihistamines and the central nervous system.
    Welch MJ; Meltzer EO; Simons FE
    Clin Allergy Immunol; 2002; 17():337-88. PubMed ID: 12113223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans?
    Cavero I; Mestre M; Guillon JM; Heuillet E; Roach AG
    Drug Saf; 1999; 21 Suppl 1():19-31; discussion 81-7. PubMed ID: 10597865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating allergic rhinitis with second-generation antihistamines.
    Nightingale CH
    Pharmacotherapy; 1996; 16(5):905-14. PubMed ID: 8888086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The current cardiac safety situation with antihistamines.
    Yap YG; Camm AJ
    Clin Exp Allergy; 1999 Mar; 29 Suppl 1():15-24. PubMed ID: 10209701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children.
    Delgado LF; Pferferman A; Solé D; Naspitz CK
    Ann Allergy Asthma Immunol; 1998 Apr; 80(4):333-7. PubMed ID: 9564984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiallergic effects of H1-receptor antagonists.
    Baroody FM; Naclerio RM
    Allergy; 2000; 55 Suppl 64():17-27. PubMed ID: 11291777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of urticaria and angioedema: low-sedating H1-type antihistamines.
    Soter NA
    J Am Acad Dermatol; 1991 Jun; 24(6 Pt 2):1084-7. PubMed ID: 1677011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative pharmacology of H1 antihistamines: clinical relevance.
    Simons FE
    Am J Med; 2002 Dec; 113 Suppl 9A():38S-46S. PubMed ID: 12517581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis.
    Bender BG; Berning S; Dudden R; Milgrom H; Tran ZV
    J Allergy Clin Immunol; 2003 Apr; 111(4):770-6. PubMed ID: 12704356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug interactions with the nonsedating antihistamines.
    Ament PW; Paterson A
    Am Fam Physician; 1997 Jul; 56(1):223-31. PubMed ID: 9225677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic advantages of third generation antihistamines.
    Handley DA; Magnetti A; Higgins AJ
    Expert Opin Investig Drugs; 1998 Jul; 7(7):1045-54. PubMed ID: 15992014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in the pharmacotherapy of allergic rhinitis: second-generation H1-receptor antagonists.
    Corey JP
    Otolaryngol Head Neck Surg; 1993 Sep; 109(3 Pt 2):584-92. PubMed ID: 8105440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-generation antihistamines for the treatment of chronic idiopathic urticaria.
    Belsito DV
    J Drugs Dermatol; 2010 May; 9(5):503-12. PubMed ID: 20480793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New insights into the second generation antihistamines.
    Walsh GM; Annunziato L; Frossard N; Knol K; Levander S; Nicolas JM; Taglialatela M; Tharp MD; Tillement JP; Timmerman H
    Drugs; 2001; 61(2):207-36. PubMed ID: 11270939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and central nervous system impairment of newer-generation prescription antihistamines in seasonal allergic rhinitis.
    Spangler DL; Brunton S
    South Med J; 2006 Jun; 99(6):593-9. PubMed ID: 16800414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.